SCHEMBL862671

SCHEMBL862671

Cc1ccc2c(c1)c(-c1ccc[nH]c1=O)c(C(=O)NS(=O)(=O)C1CC1)n2Cc1cc(OC(F)(F)F)ccc1F

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.38
MOGAT2 Q3SYC2 3/20 0.38
CYP2C9 P11712 2/20 0.38
MGAT2 Q10469 4/20 0.37
SERPINE1 P05121 1/20 0.35
SCN9A Q15858 6/20 0.35
SCN5A Q14524 5/20 0.35
ABL1 P00519 1/20 0.35
IDH1 O75874 1/20 0.34
AURKA O14965 1/20 0.33
TPX2 Q9ULW0 1/20 0.33
PPARG P37231 1/20 0.32
SCN2B O60939 1/20 0.32
SCN1A P35498 1/20 0.32
SCN1B Q07699 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10256456 0.92 CYP2C8 (0.42) CYP2C8MOGAT2CYP2C9MGAT2SCN9A
SCHEMBL831741 0.90 CYP2C8 (0.41) CYP2C8MOGAT2CYP2C9MGAT2SCN9A
SCHEMBL831674 0.88 CYP2C8 (0.43) CYP2C8MOGAT2CYP2C9MGAT2SCN9A
SCHEMBL831189 0.88 CYP2C8 (0.39) CYP2C8MOGAT2CYP2C9MGAT2SCN9A
SCHEMBL831769 0.87 CYP2C8 (0.39) CYP2C8MOGAT2CYP2C9MGAT2SCN9A
SCHEMBL831989 0.87 CYP2C8 (0.39) CYP2C8MOGAT2CYP2C9MGAT2SCN9A
SCHEMBL831826 0.87 CYP2C8 (0.39) CYP2C8MOGAT2CYP2C9MGAT2SCN9A
SCHEMBL831390 0.87 CYP2C8 (0.39) CYP2C8MOGAT2CYP2C9MGAT2SCN9A
SCHEMBL832311 0.86 CYP2C8 (0.37) CYP2C8MOGAT2CYP2C9MGAT2SCN9A
SCHEMBL13905361 0.86 CYP2C8 (0.38) CYP2C8MOGAT2CYP2C9MGAT2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885MOGAT2 2114/4885CYP2C9 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.